Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment

References

• Peters SP, Ferguson G, Deniz Y, et al. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med 2006;100:1139-51
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Data, statistics, and surveillance. Atlanta, GA: CDC, 2015. Available at: https://www.cdc.gov/asthma/asthmadata.htm [Last accessed November 23, 2017]
   Google Scholar
• Eurostat. Respiratory disease statistics. Available at: http://ec.europa.eu/eurostat/statistics-explained/index.php/Respiratory_diseases_statistics [Last accessed January 2017]
   Google Scholar
• Selroos OKM, Lscwik P, Bousquet J, et al. National and regional asthma programmes in Europe. Eu Respir Rev 2015;24:474-83
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. GINA, 2016. Available at: http://ginasthma.org/ [Last accessed August 22, 2016]
   Google Scholar
• O’Neill S, Sweeney J, Patterson CC, et al. The cost of treating severe refractory asthma in the UK: An economic analysis from the British Thoracic Society Difficult Asthma Registry. Thorax 2015;70:376-8
   PubMed Web of Science ®Google Scholar
• Bahadori K, Doyle-Waters MM, Marra C, et al. Economic burden of asthma: a systematic review. BMC Pulm Med 2009;9:24
   PubMedGoogle Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med 2009;6:e1000097
   PubMed Web of Science ®Google Scholar
• Methley AM, Campbell S, Chew-Graham C, et al. PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res 2014;14:579
   PubMed Web of Science ®Google Scholar
• Centre for Evidence-Based Medicine. OCEBM 2011 Levels of Evidence. Oxford, UK: CEBM; 2011. Available at: http://www.cebm.net/wp-content/uploads/2014/06/CEBM-Levels-of-Evidence-2.1.pdf [Last accessed November 24, 2017]
   Google Scholar
• Nelsen L, Suruki R, Albers F, et al. Characterization of a severe asthma patient population with and without eosinophilic inflammation and frequent exacerbations by multiple PROs (IDEAL). Poster session presented at: 112th International Conference of the American Thoracic Society (ATS); May 13–18, 2016; San Francisco, CA
   Google Scholar
• Cohen DJ, Annunziata K, Isherwood G. Profile and perspective of patients with severe allergic asthma and those receiving omalizumab: Findings from the National Health and Wellness Survey 2010. Poster presented at: 109th International Conference of the American Thoracic Society (ATS); May 17–22, 2013; Philadelphia, PA
   Google Scholar
• Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 2016;388:31-44
   PubMed Web of Science ®Google Scholar
• Matsunaga K, Akamatsu K, Miyatake A, et al. Natural history and risk factors of obstructive changes over a 10-year period in severe asthma. Respir Med 2013;107:355-60
   PubMed Web of Science ®Google Scholar
• Li J, Kang J, Wang C, et al. Omalizumab improves quality of life and asthma control in Chinese patients with moderate to severe asthma: A randomized phase III study. Allergy Asthma Immunol Res 2016;8:319-28
   PubMed Web of Science ®Google Scholar
• Park HS, Kim MK, Imai N, et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. Int Arch Allergy Immunol 2016;169:135-45
   PubMed Web of Science ®Google Scholar
• Choi JS, Jang AS, Park JS, et al. Role of neutrophils in persistent airway obstruction due to refractory asthma. Respirology 2012;17:322-9
   PubMed Web of Science ®Google Scholar
• Matsunaga K, Hirano T, Akamatsu K, et al. Predictors for identifying the efficacy of systemic steroids on sustained exhaled nitric oxide elevation in severe asthma. Allergol Int 2013;62:359-65
   PubMed Web of Science ®Google Scholar
• Tajiri T, Niimi A, Matsumoto H, et al. Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study. Ann Allergy Asthma Immunol 2014;113:470-5
   PubMed Web of Science ®Google Scholar
• Radhakrishna N, Tay T, Hore-Lacy F, et al. Profile of difficult to treat asthma patients referred for systematic assessment. Respir Med 2016;117:166-73
   PubMed Web of Science ®Google Scholar
• Gibson PG, Reddel H, McDonald VM, et al. Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry. Intern Med J 2016;46:1054-62
   PubMed Web of Science ®Google Scholar
• Korn S, Schumann C, Kropf C, et al. Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma. Ann Allergy Asthma Immunol 2010;105:313-19
   PubMed Web of Science ®Google Scholar
• Korn S, Both J, Jung M, et al. Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria. Ann Allergy Asthma Immunol 2011;107:474-9
   PubMed Web of Science ®Google Scholar
• Molimard M, Vervloet D, Le Gros V, et al. Insights into severe asthma control as assessed by guidelines, pulmonologist, patient, and partner. J Asthma 2010;47:853-9
   PubMed Web of Science ®Google Scholar
• Siroux V, Boudier A, Bousquet J, et al. Phenotypic determinants of uncontrolled asthma. J Allergy Clin Immunol 2009;124:681-7
   PubMed Web of Science ®Google Scholar
• Godard P, Boucot I, Pribil C, et al. [Phenotype of asthmatic patients according to a score derived from the Asthma Control Test]. Rev Mal Respir 2010;27:1039-48
   PubMed Web of Science ®Google Scholar
• Molimard M, de Blay F, Didier A, et al. Effectiveness of omalizumab (Xolair®) in the first patients treated in real-life practice in France. Respir Med 2008;102:71-6
   PubMed Web of Science ®Google Scholar
• Allegra L, Cremonesi G, Girbino G, et al. Real-life prospective study on asthma control in Italy: cross-sectional phase results. Respir Med 2012;106:205-14
   PubMed Web of Science ®Google Scholar
• Caminati M, Senna G, Chieco Bianchi F, et al. Omalizumab management beyond clinical trials: the added value of a network model. Pulm Pharmacol Ther 2014;29:74-9
   PubMed Web of Science ®Google Scholar
• Cazzola M, Camiciottoli G, Bonavia M, et al. Italian real-life experience of omalizumab. Respir Med 2010;104:1410-6
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Guerriero M, Micheletto C, et al. Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study. J Asthma 2011;48:437-41
   PubMed Web of Science ®Google Scholar
• Dente FL, Carnevali S, Bartoli ML, et al. Profiles of proinflammatory cytokines in sputum from different groups of severe asthmatic patients. Ann Allergy Asthma Immunol 2006;97:312-20
   PubMed Web of Science ®Google Scholar
• Maio S, Baldacci S, Cerrai S, et al. The Italian registry for severe/uncontrolled asthma. Presented at: Congress of the European Respiratory Society (ERS); September 3-7, 2016; London, UK
   Google Scholar
• Novelli F, Latorre M, Vergura L, et al. Asthma control in severe asthmatics under treatment with omalizumab: a cross-sectional observational study in Italy. Pulm Pharmacol Ther 2015;31:123-9
   PubMed Web of Science ®Google Scholar
• Novelli F, Latorre M, Lenzini G, et al. Relationship between clinical-functional findings and biomarkers in patients with severe asthma. Presented at: 109th International Conference of the American Thoracic Society (ATS); May 17-22, 2013; Philadelphia, PA
   Google Scholar
• Hermosa JL, Sanchez CB, Rubio MC, et al. Factors associated with the control of severe asthma. J Asthma 2010;47:124-30
   PubMed Web of Science ®Google Scholar
• Quirce S, Plaza V, Picado C, et al. Prevalence of uncontrolled severe persistent asthma in pneumology and allergy hospital units in Spain. J Investig Allergol Clin Immunol 2011;21:466-71
   PubMed Web of Science ®Google Scholar
• Vennera M, Picado C, Herráez L, et al. Factors associated with uncontrolled severe asthma and with control perception by physicians and patients. Arch Bronconeumol 2014;50:384-91
   PubMed Web of Science ®Google Scholar
• Vennera Mdel C, Perez De Llano L, Bardagi S, et al. Omalizumab therapy in severe asthma: experience from the Spanish registry–some new approaches. J Asthma 2012;49:416-22
   PubMed Web of Science ®Google Scholar
• Lebrón-Ramos JM, de Rota-García LF, Padilla-Galo A, et al. Experience with omalizumab in the treatment of patients with severe allergic asthma: A first approach at 16 weeks. Poster session presented at: 10th World Congress on Sleep Apnea, Sleep Respiratory Disorders and Snoring (WCSA); August 27–September 1, 2012; Rome, Italy
   Google Scholar
• Bumbacea D, Campbell D, Nguyen L, et al. Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J 2004;24:122-8
   PubMed Web of Science ®Google Scholar
• Chaudhuri R, McSharry C, Heaney LG, et al. Effects of older age and age of asthma onset on clinical and inflammatory variables in severe refractory asthma. Respir Med 2016;118:46-52
   PubMed Web of Science ®Google Scholar
• Gonem S, Umar I, Burke D, et al. Airway impedance entropy and exacerbations in severe asthma. Eur Respir J 2012;40:1156-63
   PubMed Web of Science ®Google Scholar
• Mansur A, Afridi L, Sullivan J, et al. Continuous terbutaline infusion in severe asthma in adults: a retrospective study of long-term efficacy and safety. J Asthma 2014;51:1076-82
   PubMed Web of Science ®Google Scholar
• Menzies D, Jackson C, Mistry C, et al. Symptoms, spirometry, exhaled nitric oxide, and asthma exacerbations in clinical practice. Ann Allergy Asthma Immunol 2008;101:248-55
   PubMed Web of Science ®Google Scholar
• Sweeney J, Patterson CC, Menzies-Gow A, et al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. Thorax 2016;71:339-46
   Google Scholar
• Hayes G, Masoli M, Whalley B, et al. Fungal sensitisation and bronchiectasis in a severe asthma clinic. Thorax 2013;68:A49
   Web of Science ®Google Scholar
• Niven RM, Saralaya D, Chaudhuri R, et al. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study). BMJ Open 2016;6:e011857
   PubMed Web of Science ®Google Scholar
• Abadoglu O, Berk S. Tiotropium may improve asthma symptoms and lung function in asthmatic patients with irreversible airway obstruction: the real-life data. Clin Respir J 2016;10:421-7
   PubMed Web of Science ®Google Scholar
• Alfarroba S, Videira W, Galvao-Lucas C, et al. Clinical experience with omalizumab in the severe asthma unit. Rev Port Pneumol 2014;20:78-83
   PubMed Web of Science ®Google Scholar
• Amelink M, de Groot JC, de Nijs SB, et al. Severe adult-onset asthma: A distinct phenotype. J Allergy Clin Immunol 2013;132:336-41
   PubMed Web of Science ®Google Scholar
• Bachert C, van Steen K, Zhang N, et al. Specific IgE against staphylococcus aureus enterotoxins: an independent risk factor for asthma. J Allergy Clin Immunol 2012;130:376-81
   PubMed Web of Science ®Google Scholar
• Breekveldt-Postma NS, Erkens JA, Aalbers R, et al. Extent of uncontrolled disease and associated medical costs in severe asthma–a PHARMO study. Curr Med Res Opin 2008;24:975-83
   PubMed Web of Science ®Google Scholar
• Delimpoura V, Bakakos P, Tseliou E, et al. Increased levels of osteopontin in sputum supernatant in severe refractory asthma. Thorax 2010;65:782-6
   PubMed Web of Science ®Google Scholar
• Gaga M, Papageorgiou N, Yiourgioti G, et al. Risk factors and characteristics associated with severe and difficult to treat asthma phenotype: an analysis of the ENFUMOSA group of patients based on the ECRHS questionnaire. Clin Exp Allergy 2005;35:954-9
   PubMed Web of Science ®Google Scholar
• Gemicioglu B, Caliskaner Ozturk B, Duman B. Comparison of allergic asthma patients treated with omalizumab and non-allergic patients treated with continuous oral corticosteroids: results of five year follow-up therapies. Tuberk Toraks 2016;64:97-104
   PubMed Web of Science ®Google Scholar
• Hekking PPW, Wener RR, Amelink M, et al. The prevalence of severe refractory asthma. J Allergy Clin Immunol 2015;135:896-902
   PubMed Web of Science ®Google Scholar
• Potoczek A. Gender and presence of profound psychological traumas versus the presence and intensity of panic disorder in difficult and severe asthma and aspirin-induced asthma of different severity. Psychoterapia 2011;13:59-65
   Google Scholar
• Schleich F, Brusselle G, Louis R, et al. Cross-sectional analysis of the Belgian severe asthma registry. Presented at: Annual Congress of the European Respiratory Society (ERS); September 1-5, 2012; Vienna, Austria
   Google Scholar
• Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J 2015;46:1308-21
   PubMed Web of Science ®Google Scholar
• Smetanenko TV, Kobiakova OS, Ogorodova LM, et al. [Life quality control in patients with severe bronchial asthma]. Klin Med (Mosk) 2006;84:28-31
   PubMedGoogle Scholar
• Subramaniam A, Al-Alawi M, Hamad S, et al. A study into efficacy of omalizumab therapy in patients with severe persistent allergic asthma at a tertiary referral centre for asthma in Ireland. QJM 2013;106:631-4
   PubMed Web of Science ®Google Scholar
• Ten Brinke A, Sterk PJ, Masclee AA, et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J 2005;26:812-18
   PubMed Web of Science ®Google Scholar
• Tzortzaki EG, Georgiou A, Kampas D, et al. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean “real-life” experience. Pulm Pharmacol Ther 2012;25:77-82
   PubMed Web of Science ®Google Scholar
• van Veen IH, Ten Brinke A, Sterk PJ, et al. Airway inflammation in obese and nonobese patients with difficult-to-treat asthma. Allergy 2008;63:570-4
   PubMed Web of Science ®Google Scholar
• Zietkowski Z, Tomasiak-Lozowska MM, Skiepko R, et al. High-sensitivity C-reactive protein in the exhaled breath condensate and serum in stable and unstable asthma. Respir Med 2009;103:379-85
   PubMed Web of Science ®Google Scholar
• Sousa AS, Pereira AM, Fonseca JA, et al. Asthma control and exacerbations in patients with severe asthma treated with omalizumab in Portugal. Rev Port Pneumol (2006) 2015;21:327-33
   Web of Science ®Google Scholar
• van Nooten F, Stern S, Braunstahl GJ, et al. Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands. J Med Econ 2013;16:342-8
   PubMedGoogle Scholar
• Bavbek S, Misirligil Z, Study Group. A breath for health: an exploratory study in severe asthma patients in Turkey. Allergy 2008;63:1218-27
   PubMed Web of Science ®Google Scholar
• Izbicki G, Grosman A, Weiler Z, et al. National asthma observational survey of severe asthmatics in Israel: the no-air study. Allergy Asthma Clin Immunol 2012;8:8
   PubMed Web of Science ®Google Scholar
• Almeida PC, Souza-Machado A, Leite Mdos S, et al. Comparison between two methods of asthma control evaluation based on individual perception. J Bras Pneumol 2012;38:299-307
   PubMed Web of Science ®Google Scholar
• Dalcin PT, Menegotto DM, Zanonato A, et al. Factors associated with uncontrolled asthma in Porto Alegre, Brazil. Braz J Med Biol Res 2009;42:1097-103
   PubMed Web of Science ®Google Scholar
• de Carvalho-Pinto RM, Cukier A, Angelini L, et al. Clinical characteristics and possible phenotypes of an adult severe asthma population. Respir Med 2012;106:47-56
   PubMed Web of Science ®Google Scholar
• Gomes-Filho I, Marques K, Passos-Soares J, et al. Periodontitis is associated with severe asthma – a case–control study. 99th Annual Meeting of the American Academy of Periodontology (AAP); September 28–October 1, 2013; Philadelphia, PA
   Google Scholar
• Suzuki C, Santoni N, Silva N. Estimating the budget impact of adding omalizumab to standard therapy in patients with uncontrolled severe allergic asthma from private health care system perspective in Brazil. Presented at: 18th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 18-22, 2013; New Orleans, LA
   Google Scholar
• Broder MS, Chang EY, Sapra S. Care of asthma patients in relation to guidelines. Allergy Asthma Proc 2010;31:452-60
   PubMed Web of Science ®Google Scholar
• Calhoun WJ, Haselkorn T, Mink DR, et al. Clinical burden and predictors of asthma exacerbations in patients on guideline-based steps 4–6 asthma therapy in the TENOR cohort. J Allergy Clin Immunol Pract 2014;2:193-200
   PubMed Web of Science ®Google Scholar
• Denlinger L, Phillips B, Ramratnam S, et al. Inflammatory and co-morbid features of patients with severe asthma and frequent exacerbations. Am J Respir Crit Care Med 2016;195:302-13
   Web of Science ®Google Scholar
• Janson SL, Solari PG, Trzaskoma B, et al. Omalizumab adherence in an observational study of patients with moderate to severe allergic asthma. Ann Allergy Asthma Immunol 2015;114:516-21
   PubMed Web of Science ®Google Scholar
• Miranda C, Busacker A, Balzar S, et al. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004;113:101-8
   PubMed Web of Science ®Google Scholar
• Peters AT, Klemens JC, Haselkorn T, et al. Insurance status and asthma-related health care utilization in patients with severe asthma. Ann Allergy Asthma Immunol 2008;100:301-7
   PubMed Web of Science ®Google Scholar
• Peters J, Singh H, Brooks EG, et al. Persistence of community-acquired respiratory distress syndrome toxin-producing Mycoplasma pneumoniae in refractory asthma. Chest 2011;140:401-7
   PubMed Web of Science ®Google Scholar
• Scott L, Li M, Thobani S, et al. Factors affecting ability to achieve asthma control in adult patients with moderate to severe persistent asthma. J Asthma 2016;53:644-9
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Campbell JD, Ghushchyan VH, et al. Outcomes before and after treatment escalation to Global Initiative for Asthma steps 4 and 5 in severe asthma. Ann Allergy Asthma Immunol 2015;114:462-9
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Campbell JD, Ghushchyan VH, et al. Characterizing the severe asthma population in the United States: claims-based analysis of three treatment cohorts in the year prior to treatment escalation. J Asthma 2015;52:669-80
   PubMed Web of Science ®Google Scholar
• Vargas-Correa J, Bracamonte-Peraza R, Espinosa-Morales S, et al. Clinical experience with omalizumab in patients with severe asthma. Real-world data. Rev Alerg Mex 2016;63:216-26
   PubMedGoogle Scholar
• Zazzali JL, Raimundo K, Trzaskoma B, et al. Changes in asthma control, work productivity, and impairment with omalizumab: 5-year EXCELS study results. Allergy Asthma Proc 2015;36:283-92
   PubMed Web of Science ®Google Scholar
• Zeiger RS, Schatz M, Dalal AA, et al. Utilization and costs of severe uncontrolled asthma in a managed-care setting. J Allergy Clin Immunol Pract 2016;4:120-9
   PubMed Web of Science ®Google Scholar
• Chastek B, Korrer S, Altan A, et al. The few who use the most care: Costs of severe and persistent asthma in a UD managed care plan. Am J Respir Crit Care Med 2015;191:A4164
   Google Scholar
• National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the diagnosis and management of asthma-summary Report. J Allergy Clin Immunol 2007;120:S94-138
   PubMed Web of Science ®Google Scholar
• Fernandes AG, Souza-Machado C, Coelho RC, et al. Risk factors for death in patients with severe asthma. J Bras Pneumol 2014;40:364-72
   PubMed Web of Science ®Google Scholar
• Chastek B, Korrer S, Nagar SP, et al. Economic burden of illness among patients with severe asthma in a managed care setting. J Manag Care Spec Pharm 2016;22:848-61
   PubMedGoogle Scholar
• British Thoracic Society. BTS/SIGN guideline for the management of asthma. London, UK: British Thoracic Society, 2016. Available at: https://www.brit-thoracic.org.uk/standards-of-care/guidelines/btssign-british-guideline-on-the-management-of-asthma/ [Last accessed November 15, 2017]
   Google Scholar
• Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004;113:59-65
   PubMed Web of Science ®Google Scholar
• Juniper EF, O'Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14:902-7
   PubMed Web of Science ®Google Scholar
• Bateman E, Karpel J, Casale T, et al. Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma. Chest 2006;129:1176-87
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016;388:2115-27
   PubMed Web of Science ®Google Scholar
• Bousquet J, Siergiejko Z, Swiebocka E, et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy 2011;66:671-8
   PubMed Web of Science ®Google Scholar
• Braunstahl G, Chlumsky J, Peachey G, et al. Reduction in oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma receiving omalizumab in a real-world setting. Clin Transl Allergy 2013;3:P132
   Google Scholar
• Brightling CE, Nordenmark LH, Jain M, et al. Effect of anti-IL-13 treatment on airway dimensions in severe asthma. Am J Respir Crit Care Med 2016;194:118-20
   PubMed Web of Science ®Google Scholar
• De Boever EH, Ashman C, Cahn AP, et al. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial. J Allergy Clin Immunol 2014;133:989-96
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016;388:2128-41
   PubMed Web of Science ®Google Scholar
• Hanania N. Efficacy and safety of lebrikizumab in severe uncontrolled asthma: results from the lute and verse phase II randomized, double-blind, placebo-controlled trials. Lancet Respir Med 2014;4:781-96
   Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309-16
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012;367:1198-207
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Moroni-Zentgraf P, Tashkin DP, et al. Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. Respir Med 2016;117:198-206
   PubMed Web of Science ®Google Scholar
• Lugogo N, Domingo C, Chanez P, et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, Phase IIIb study. Clin Ther 2016;38:2058-70
   PubMed Web of Science ®Google Scholar
• Molfino NA, Kuna P, Leff JA, et al. Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma. BMJ Open 2016;6:e007709
   PubMed Web of Science ®Google Scholar
• O'Byrne PM, Metev H, Puu M, et al. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2016;4:797-806
   PubMed Web of Science ®Google Scholar
• Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med 2016;4:549-56
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651-9
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009;179:549-58
   PubMed Web of Science ®Google Scholar
• Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015;3:355-66
   PubMed Web of Science ®Google Scholar
• Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2014;2:878-90
   Web of Science ®Google Scholar
• Karpel JP, Nayak A, Lumry W, et al. Inhaled mometasone furoate reduces oral prednisone usage and improves lung function in severe persistent asthma. Respir Med 2007;101:628-37
   PubMed Web of Science ®Google Scholar
• Chen HC, Huang CD, Chang E, et al. Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study. BMC Pulm Med 2016;16:3
   Google Scholar
• Hoshino M, Ohtawa J. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. Respiration 2012;83:520-8
   PubMed Web of Science ®Google Scholar
• Inoue H, Komori M, Matsumoto T, et al. Effects of salmeterol in patients with persistent asthma receiving inhaled corticosteroid plus theophylline. Respiration 2007;74:611-16
   PubMed Web of Science ®Google Scholar
• Obase Y, Shimoda T, Matsuse H, et al. The position of pranlukast, a cysteinyl leukotriene receptor antagonist, in the long-term treatment of asthma. 5-year follow-up study. Respiration 2004;71:225-32
   PubMed Web of Science ®Google Scholar
• Rajanandh MG, Nageswari AD, Prathiksha G. Effectiveness of vitamin D3 in severe persistent asthmatic patients: a double blind, randomized, clinical study. J Pharmacol Pharmacother 2015;6:142-6
   PubMed Web of Science ®Google Scholar
• Sano Y, Adachi M, Kiuchi T, et al. Effects of nebulized sodium cromoglycate on adult patients with severe refractory asthma. Respir Med 2006;100:420-33
   PubMed Web of Science ®Google Scholar
• Tajiri T, Niimi A, Matsumoto H, et al. Efficacy of omalizumab in patients with severe refractory asthma: A comprehensive study. Presented at: 108th International Conference of the American Thoracic Society (ATS); May 18-23, 2012; San Francisco, CA
   Google Scholar
• Takeyama K, Kondo M, Tagaya E, et al. Budesonide/formoterol maintenance and reliever therapy in moderate-to-severe asthma: effects on eosinophilic airway inflammation. Allergy Asthma Proc 2014;35:141-7
   PubMed Web of Science ®Google Scholar
• Udwadia Z, Narasimhan R, Ratnavelu V, et al. Efficacy and safety of omalizumab in real-world clinical practice in Indian patients with allergic (IgE-mediated) asthma: Analysis by baseline severity of asthma. Thorax 2013;68:167
   Google Scholar
• Hew M, Gillman A, Sutherland M, et al. Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria. Clin Exp Allergy 2016;46:1407-15
   PubMed Web of Science ®Google Scholar
• Korn S, Haasler I, Fliedner F, et al. Monitoring free serum IgE in severe asthma patients treated with omalizumab. Respir Med 2012;106:1494-500
   PubMed Web of Science ®Google Scholar
• Korn S, Thielen A, Seyfried S, et al. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med 2009;103:1725-31
   PubMed Web of Science ®Google Scholar
• Schumann C, Kropf C, Wibmer T, et al. Omalizumab in patients with severe asthma: the XCLUSIVE study. Clin Respir J 2012;6:215-27
   PubMed Web of Science ®Google Scholar
• Velling P, Skowasch D, Pabst S, et al. Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy. Eur J Med Res 2011;16:407-10
   PubMed Web of Science ®Google Scholar
• Molimard M, Mala L, Bourdeix I, et al. Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control. Respir Med 2014;108:571-6
   PubMed Web of Science ®Google Scholar
• Brusselle G, Michils A, Louis R, et al. "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med 2009;103:1633-42
   PubMed Web of Science ®Google Scholar
• Bateman ED, Bousquet J, Keech ML, et al. The correlation between asthma control and health status: the GOAL study. Eur Respir J 2007;29:56-62
   PubMed Web of Science ®Google Scholar
• Nascimento-Sampaio F, Leite Mdos S, Leopold D, et al. Influence of upper airway abnormalities on the control of severe asthma: a cross-sectional study. Int Forum Allergy Rhinol 2015;5:371-9
   PubMed Web of Science ®Google Scholar
• Caminati M, Senna G, Stefanizzi G, et al. Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience. BMC Pulm Med 2016;16:128
   PubMed Web of Science ®Google Scholar
• Dente FL, Bacci E, Bartoli ML, et al. Effects of oral prednisone on sputum eosinophils and cytokines in patients with severe refractory asthma. Ann Allergy Asthma Immunol 2010;104:464-70
   PubMed Web of Science ®Google Scholar
• Ancochea J, Chivato T, Casan P, et al. Profile of patients treated with omalizumab in routine clinical practice in Spain. Allergol Immunopathol (Madr) 2014;42:102-8
   PubMed Web of Science ®Google Scholar
• Perez De Llano LA, Gonzalez FC, Anon OC, et al. [Relationship between comorbidity and asthma control]. Arch Bronconeumol 2010;46:508-13
   PubMed Web of Science ®Google Scholar
• Chiner E, Fernandez-Fabrellas E, Landete P, et al. Comparison of costs and clinical outcomes between hospital and outpatient administration of omalizumab in patients with severe uncontrolled asthma. Arch Bronconeumol 2016;52:211-16
   PubMed Web of Science ®Google Scholar
• Britton M, Howes T, Saralaya D, et al. Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Real-life data from 3 UK centres. Presented at: Annual Congress of the European Respiratory Society; September 1-5, 2012; Vienna, Austria
   Google Scholar
• Edgecombe K, Latter S, Peters S, et al. Health experiences of adolescents with uncontrolled severe asthma. Arch Dis Child 2010;95:985-91
   PubMed Web of Science ®Google Scholar
• Gamble J, Stevenson M, Heaney LG. A study of a multi-level intervention to improve non-adherence in difficult to control asthma. Respir Med 2011;105:1308-15
   PubMed Web of Science ®Google Scholar
• Gamble J, Stevenson M, McClean E, et al. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med 2009;180:817-22
   PubMed Web of Science ®Google Scholar
• Gordon H, Patel P, Hull J, et al. NAFLD in patients with severe asthma. Liver 2013;62:A89-90
   Google Scholar
• Grainge C, Jayasekera N, Dennison P, et al. Mycophenolate mofetil improves lung function and symptoms in severe treatment resistant asthma. Respirology 2013;18:12
   Google Scholar
• Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-84
   PubMed Web of Science ®Google Scholar
• Mansur A, Mitchell V, Alfridi L, et al. Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: UK centre real-life experience. Thorax 2013;68:170
   Google Scholar
• Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 2013;68:322-9
   PubMed Web of Science ®Google Scholar
• Hashimoto S, Brinke AT, Roldaan AC, et al. Internet-based tapering of oral corticosteroids in severe asthma: a pragmatic randomised controlled trial. Thorax 2011;66:514-20
   PubMed Web of Science ®Google Scholar
• Havlucu Y, Yorgancioglu A, Kurhan F, et al. Omalizumab in patients with severe persistent asthma in real life setting in Manisa, Turkey. Poster session presented at: 33rd Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI); June 7-11, 2014; Copenhagen, Denmark
   Google Scholar
• Kerstjens HA, Disse B, Schroder-Babo W, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol 2011;128:308-14
   PubMed Web of Science ®Google Scholar
• Kupczyk M, Haque S, Middelveld RJM, et al. Phenotypic predictors of response to oral glucocorticosteroids in severe asthma. Respir Med 2013;107:1521-30
   PubMed Web of Science ®Google Scholar
• Niven R, Chung KF, Panahloo Z, et al. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Respir Med 2008;102:1371-8
   PubMed Web of Science ®Google Scholar
• Pereira Barbosa M, Bugalho de Almeida A, Pereira C, et al. Real-life efficacy and safety of omalizumab in Portuguese patients with persistent uncontrolled asthma. Rev Port Pneumol (2006) 2015;21:151-6
   PubMed Web of Science ®Google Scholar
• Sadigov A, Agayeva K, Guliyeva S, et al. Tiotropium in uncontrolled and severe bronchial asthma: Can we modify the treatment of severe disease? Am J Respir Crit Care Med 2013;187:A1268
   Web of Science ®Google Scholar
• Ferreira D, Duarte R, Carvalho A. [Exacerbations in severe persistent asthma–impact of risk factors control]. Rev Port Pneumol 2007;13:675-89
   PubMedGoogle Scholar
• Herrera-Garcia J, Sanchez-Casas G, Arellano-Jaramillo L, et al. Omalizumab in the treatment of persistent moderate to severe asthma in the context of allergic and non-allergic asthma. Med Int Mex 2015;31:693-700
   Google Scholar
• Lopez Tiro JJ, Contreras EA, del Pozo ME, et al. Real life study of three years omalizumab in patients with difficult-to-control asthma. Allergol Immunopathol (Madr) 2015;43:120-6
   PubMed Web of Science ®Google Scholar
• Rubin AS, Souza-Machado A, Andradre-Lima M, et al. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX). J Asthma 2012;49:288-93
   PubMed Web of Science ®Google Scholar
• Aburuz S, McElnay J, Gamble J, et al. Relationship between lung function and asthma symptoms in patients with difficult to control asthma. J Asthma 2005;42:859-64
   PubMed Web of Science ®Google Scholar
• Al Kassar Y, El-Sameed Y, Hassan A, et al. Assessment of omalizumab safety in patients with severe persistent allergic asthma three months after initiation of therapy. Presented at: 17th Congress of the Asian Pacific Society of Respirology (APSR 2012); December 14-16, 2012; Hong Kong, China
   Google Scholar
• Çaliskaner Öztürk B, Duman B, Gemicioglu B. Five year follow-up of asthma control in severe asthma patients treated with and without omalizumab. Poster session presented at: 16th Annual Congress of the Turkish Thoracic Society; April 3-7, 2013; Antalaya, Turkey
   Google Scholar
• Havlucu Y, Yorgancioglu A, Kurhan F, et al. Long term effect of anti-IgE (omalizumab) treatment on asthma control in patients with uncontrolled severe persistent asthma: Real life study. Poster session presented at: 16th Annual Congress of the Turkish Thoracic Society; April 3-7, 2013; Antalaya, Turkey
   Google Scholar
• Ozgur ES, Ozge C, Ilvan A, et al. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma. J Asthma 2013;50:687-94
   PubMed Web of Science ®Google Scholar
• Rottem M. Omalizumab reduces corticosteroid use in patients with severe allergic asthma: real-life experience in Israel. J Asthma 2012;49:78-82
   PubMed Web of Science ®Google Scholar
• Zakaria M, Abu-Hussein S, Abu-Hussein A, et al. The effect of omalizumab in treatment of inadequate controlled severe persistent asthma patient. Chest 2013;144:76A
   Web of Science ®Google Scholar
• Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health 2014;17:5-14
   PubMed Web of Science ®Google Scholar
• Bardelas J, Figliomeni M, Kianifard F, et al. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma. J Asthma 2012;49:144-52
   PubMed Web of Science ®Google Scholar
• Lafeuille MH, Dean J, Zhang J, et al. Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma. Ann Allergy Asthma Immunol 2012;109:59-64
   PubMed Web of Science ®Google Scholar
• Lafeuille MH, Duh MS, Zhang J, et al. Concomitant asthma medication use in patients receiving omalizumab: results from three large insurance claims databases. J Asthma 2011;48:923-30
   PubMed Web of Science ®Google Scholar
• Schatz M, Meckley, Kim MK, et al. Asthma exacerbation rates in adults are unchanged over a 5-year period despite high-intensity therapy. J Allergy Clin Immunol Prac 2014;2:570-4
   PubMed Web of Science ®Google Scholar
• Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013;368:2455-66
   PubMed Web of Science ®Google Scholar
• Julien JY, Martin JG, Ernst P, et al. Prevalence of obstructive sleep apnea-hypopnea in severe versus moderate asthma. J Allergy Clin Immunol 2009;124:371-6
   PubMed Web of Science ®Google Scholar
• Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011;184:1125-32
   PubMed Web of Science ®Google Scholar
• Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011;154:573-82
   PubMed Web of Science ®Google Scholar
• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343-73
   PubMed Web of Science ®Google Scholar
• von Bulow A, Kriegbaum M, Backer V, et al. The prevalence of severe asthma and low asthma control among Danish adults. J Allergy Clin Immunol Pract 2014;2:759
   PubMed Web of Science ®Google Scholar
• Barnes N, Radwan A. The APEX Study: A retrospective review of the effects of omalizumab treatment on patient-reported outcomes in severe allergic asthma patients in UK clinical practice. Presented at: 108th International Conference of the American Thoracic Society (ATS); May 18–23, 2012; San Francisco, CA
   Google Scholar
• Grimaldi-Bensouda L, Zureik M, Aubier M, et al. Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: Results from a large cohort of patients with severe uncontrolled asthma. Chest 2013;143:398-405
   PubMed Web of Science ®Google Scholar
• Chanez P, Contin-Bordes C, Garcia G, et al. Omalizumab-induced decrease of FcxiRI expression in patients with severe allergic asthma. Respir Med 2010;104:1608-17
   PubMed Web of Science ®Google Scholar
• Somerville L, Bardelas J, Viegas A, et al. Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma. Curr Med Res Opin 2014;30:59-66
   PubMed Web of Science ®Google Scholar
• Garcia G, Magnan A, Chiron R, et al. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest 2013;144:411-19
   PubMed Web of Science ®Google Scholar
• Barnes N, Mansur A, Menzies-Gow A, et al. The APEX Study: A retrospective review of outcomes in patients with severe allergic asthma who were or were not hospitalised in the year prior to omalizumab initiation in UK clinical practice. Poster session presented at: Annual Congress of the European Respiratory Society; September 1–5, 2012; Vienna, Austria
   Google Scholar
• Dal Negro RW, Tognella S, Pradelli L. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy. J Asthma 2012;49:843-8
   PubMed Web of Science ®Google Scholar
• Morjaria JB, Chauhan AJ, Babu KS, et al. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax 2008;63:584-91
   PubMed Web of Science ®Google Scholar
• Humbert M, de Blay F, Garcia G, et al. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy 2009;64:1194-201
   PubMed Web of Science ®Google Scholar
• Schreiber J, Garg K, Mailaender C. X-Tab: Non-interventional study to assess patient-related mid-term outcomes of omalizumab therapy in severe allergic asthmatic patients. Poster session presented at: 2016 Congress of the European Respiratory Society (ERS); September 3-7, 2016; London, UK
   Google Scholar
• Humbert M, Boulet LP, Niven RM, et al. Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis. Allergy 2009;64:81-4
   PubMed Web of Science ®Google Scholar
• Jain S, Saralaya D, Regan K, et al. Real life effectiveness of omalizumab in severe allergic asthma, does the IgE level matter? A Bradford experience. Poster session presented at: European Respiratory Society; September 7-11, 2013; Barcelona, Spain
   Google Scholar
• Leggett JJ, Johnston BT, Mills M, et al. Prevalence of gastroesophageal reflux in difficult asthma: relationship to asthma outcome. Chest 2005;127:1227-31
   PubMed Web of Science ®Google Scholar
• Peters JB, Rijssenbeek-Nouwens LH, Bron AO, et al. Health status measurement in patients with severe asthma. Respir Med 2014;108:278-86
   PubMed Web of Science ®Google Scholar
• Beloglazov V, Popenko Y, Du Buske L. Effect of roflumilast on asthma control in moderate and severe asthma patients. Poster session presented at: 70th Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI); February 28–March 4, 2014; San Diego, CA
   Google Scholar
• Juniper EF, Guyatt GH, Epstein RS, et al. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992;47:76-83
   PubMed Web of Science ®Google Scholar
• Perez-de-Llano LA, Carballada F, Castro Anon O, et al. Exhaled nitric oxide predicts control in patients with difficult-to-treat asthma. Eur Respir J 2010;35:1221-7
   PubMed Web of Science ®Google Scholar
• Braunstahl GJ, Canvin J, Peachey G, et al. Healthcare resource utilization in patients receiving omalizumab for allergic asthma in a real-world setting. Biol Ther 2014;4:57-67
   PubMedGoogle Scholar
• Kim SH, Kim TW, Kwon JW, et al. Economic costs for adult asthmatics according to severity and control status in Korean tertiary hospitals. J Asthma 2012;49:303-9
   PubMed Web of Science ®Google Scholar
• Sadatsafavi M, Lynd L, Marra C, et al. Direct health care costs associated with asthma in British Columbia. Can Respir J 2010;17:74-80
   PubMed Web of Science ®Google Scholar
• Pedrini A, Rossi E, Calabria S, et al. Burden of disease and health care costs of adult patients with severe refractory asthma in a big real-world database (Arco). Value Health 2016;19:A61
   Google Scholar
• Norman G, Faria R, Paton F, et al. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technol Assess 2013;17:1-342
   PubMed Web of Science ®Google Scholar
• Saralaya D, Regan K, Rothwell E, et al. Real-life effectiveness of omalizumab in reducing healthcare utilization in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital. Am J Resp Crit Care Med 2012;185:A4228
   Google Scholar
• Chuchalin AG, Ogorodova LM, Petrovskii FI, et al. [Monitoring and treatment of severe bronchial asthma in adults: results of national multicenter trial NABAT]. Ter Arkh 2005;77:36-42
   PubMed Web of Science ®Google Scholar
• Grimaldi-Bensouda L, Zureik M, Aubier M, et al. Effectiveness of omalizumab on asthma exacerbations following its introduction in a large cohort of patients with severe uncontrolled asthma. Presented at: 28th Annual International Conference on Pharmacoepidemiology and Therapeutic Risk Management of the International Society for Pharmacoepidemiology (ISPE); August 23-26, 2012; Barcelona, Spain
   Google Scholar
• Neffen H, Gonzalez SN, Fritscher CC, et al. The burden of unscheduled health care for asthma in Latin America. J Investig Allergol Clin Immunol 2010;20:596-601
   PubMed Web of Science ®Google Scholar
• Hankin C, Bronstone A, Wang Z, et al. Estimated prevalence and economic burden of severe, uncontrolled asthma in the United States. J Allergy Clin Immunol 2013;131:AB126
   Web of Science ®Google Scholar
• Turner SJ, Nazareth T, Raimundo K, et al. Impact of omalizumab on all-cause and asthma-related health care resource utilisation in patients with moderate or severe persistent asthma. Value Health 2014;17:A599
   PubMed Web of Science ®Google Scholar
• Manson SC, Brown RE, Cerulli A, et al. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med 2009;103:975-94
   PubMed Web of Science ®Google Scholar
• Lefebvre P, Duh MS, Lafeuille MH, et al. Acute and chronic systemic corticosteroid-related complications in patients with severe asthma. J Allergy Clin Immunol 2015;136:1488-95
   PubMed Web of Science ®Google Scholar
• Baiardini I, Braido F, Brandi S, et al. The impact of GINA suggested drugs for the treatment of asthma on health-related quality of life: a GA(2)LEN review. Allergy 2008;63:1015-30
   PubMed Web of Science ®Google Scholar
• Kerkhof M, Tran TN, Soriano JB, et al. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax 2018;73:116-24
   PubMed Web of Science ®Google Scholar
• Price DB, Rigazio A, Campbell JD, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med 2015;3:849-58
   PubMed Web of Science ®Google Scholar
• D’Amato G, Vitale C, Molino A, et al. Asthma-related deaths. Multidiscip Respir Med 2016;11:37
   PubMed Web of Science ®Google Scholar
• Price D, Bjermer L, Bergin DA, et al. Asthma referrals: a key component of asthma management that needs to be addressed. J Asthma Allergy 2017;10:209-23
   PubMed Web of Science ®Google Scholar
• Royal College of Physicians. Why asthma still kills: The National Review of Asthma Deaths (NRAD). London, UK: RCP, 2014. Available at: https://www.rcplondon.ac.uk/file/868/download?token=JQzyNWUs [Last accessed July 2018]
   Google Scholar